import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-diabetes-market-report';

/**
 * Curated copy for the UAE diabetes & metabolic programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 380–440M 2026 → ~USD 652M 2030, ~14% CAGR).
 * Epidemiology: ~19% adult T2DM prevalence (IDF / UAE published ranges, applied as planning inputs).
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_DIABETES_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Diabetes & Metabolic Market Report 2026',
  metaTitle: 'UAE Diabetes Market Report 2026 | BioNixus',
  metaDescription:
    'UAE diabetes & metabolic market ~USD 380–440M in 2026 (BioNixus analysis): ~19% adult T2DM prevalence, GLP-1 and tirzepatide demand, SGLT-2 growth, MOHAP/DHA/DOH access, insured obesity care—decision-ready Gulf intelligence.',
  heroLead:
    'This briefing sizes UAE diabetes and metabolic care for commercial teams: where an affluent, insured population pulls GLP-1 and obesity therapy forward, where SGLT-2 inhibitors win on cardiorenal evidence, and where emirate-level insurer policy across MOHAP, DHA, and DOH—not registration—decides whether incretin and weight-management therapy is actually covered.',
  summaryPara1:
    'The UAE pairs one of the world’s highest diabetes burdens—adult type-2 prevalence reported near 19% in published ranges—with an affluent, heavily insured population that adopts new metabolic therapy quickly. BioNixus sizes the diabetes and metabolic market at roughly USD 380–440 million in 2026, advancing toward about USD 652 million by 2030 at roughly 14% CAGR, among the fastest-growing therapy areas in the country. Growth is led by GLP-1 receptor agonists (semaglutide and tirzepatide) spanning diabetes and a fast-expanding, partly self-pay obesity segment; accelerating SGLT-2 uptake on cardiorenal evidence; durable insulin volume; and strong CGM and digital-health adoption in private endocrinology. Access turns on the three-authority landscape (MOHAP, DHA, DOH) and on mandatory-insurance coverage rules that differ by emirate and payer. Sizing reflects BioNixus market analysis, 2026, applied alongside published prevalence ranges rather than unaudited panel extrapolation.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [GCC diabetes market report](/market-reports/gcc-diabetes-market-report) for Gulf-wide benchmarking, the [Saudi Arabia diabetes market report](/market-reports/saudi-arabia-diabetes-market-report) for the larger neighbouring market, the [UAE cardiovascular report](/market-reports/uae-cardiovascular-market-report) for cardiorenal-metabolic adjacency, [diabetes therapy research](/healthcare-market-research/therapy/diabetes) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'GLP-1 (semaglutide, tirzepatide) demand led by an affluent insured and self-pay population, with obesity use often cash-funded where insurance excludes it; emirate-level insurer coverage and prior-authorization rules differing across MOHAP, DHA, and DOH plans (Thiqa, Daman, Dubai products); SGLT-2 growth on cardiorenal and heart-failure evidence; CGM and digital-adherence adoption mature in private endocrinology; medical-tourism and wellness-clinic demand lifting weight-management volume above resident need; Ramadan fasting dose-adjustment counselling shaping adherence cycles',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE diabetes as a payer-segmented, channel-driven market: endocrinologists, primary-care physicians, and a growing set of obesity and wellness clinics share the category, while coverage rules differ by emirate and insurer. The defining 2026 dynamic is the split between insured glycaemic use and largely self-pay obesity demand for GLP-1 and dual-incretin agents—who pays determines who starts and stays on therapy. We pair bilingual physician quantitative work with payer and pharmacy depth, separate resident from medical-tourism and wellness-driven weight-management demand, and capture operational and cultural gates EU analogues miss: Ramadan fasting dose adjustment, emirate-specific prior authorization, primary-care versus specialist initiation, and the obesity-versus-diabetes framing that decides eligibility. CGM and digital adherence appear in the data but only hold as forecast inputs when device reimbursement and access reality are captured in the same study.',
  commercialOutlookParagraph:
    'The outlook to 2030 is strongly growth-oriented, paced by insurer policy and supply rather than demand. GLP-1 and dual-incretin agents will expand across both diabetes and obesity as coverage pathways mature and supply normalises; SGLT-2 inhibitors will grow on cardiorenal evidence aligned to UAE comorbidity patterns; insulin remains a steady base. Manufacturers should plan emirate-specific coverage strategies, patient-support and adherence operations, and a clear position on the self-pay obesity channel that private wellness demand is opening. Leadership should stress-test uptake by payer archetype and emirate—Abu Dhabi insured, Dubai insured, and self-pay obesity—because access mechanics and willingness to pay differ sharply before regional revenue targets are locked.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, and insurer public guidance, plus primary modules—endocrinologist and primary-care adoption surveys, payer and pharmacy interviews, and supply-and-coverage tracking where data is available. Epidemiology references use published UAE and IDF-aligned prevalence ranges (adult T2DM reported near the high-teens to ~19%) as planning inputs, separating resident from medical-tourism and wellness demand, and are not patient-level forecasts. Because insurer coverage, supply, and obesity-reimbursement policy change on short cycles, access statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the UAE diabetes market in 2026?',
      answer:
        'BioNixus market analysis sizes the UAE diabetes and metabolic market at roughly USD 380–440 million in 2026, advancing toward about USD 652 million by 2030 at roughly 14% CAGR—one of the fastest-growing therapy areas in the country. Growth is driven by very high type-2 prevalence (reported near 19% of adults in published ranges), strong GLP-1 and tirzepatide demand across diabetes and obesity, SGLT-2 uptake, and mature CGM adoption. Use the GCC diabetes market report for Gulf-wide context and the UAE healthcare market report for macro sizing.',
    },
    {
      question: 'How does insurance coverage shape diabetes access across the UAE?',
      answer:
        'Most prescribing is insurance-funded, and coverage rules differ by emirate and payer. Abu Dhabi (including Thiqa and Daman-administered benefits) and Dubai plans apply different formularies and prior-authorization criteria, while MOHAP governs federal registration. For incretin and weight-management therapy, the binding question is often whether a plan covers obesity use at all—where it does not, GLP-1 demand shifts to a self-pay channel. Teams should map coverage and prior-authorization rules per emirate and payer rather than assume a single national pathway, which is exactly what BioNixus tracks with payers and pharmacies.',
    },
    {
      question: 'Why is GLP-1 and obesity demand so significant in the UAE?',
      answer:
        'The UAE combines very high diabetes and obesity prevalence with an affluent, insured, and willing-to-pay population, so GLP-1 receptor agonists (semaglutide, tirzepatide) see strong demand across both glycaemic and weight-management use. Where insurance excludes obesity indications, demand moves to a self-pay and wellness-clinic channel that lifts volume above resident clinical need. Supply normalisation and coverage decisions therefore shape real-world share as much as clinical preference. BioNixus separates insured from self-pay and medical-tourism demand so forecasts reflect genuinely addressable, reimbursable volume.',
    },
    {
      question: 'Which diabetes and metabolic classes are growing fastest in the UAE?',
      answer:
        'GLP-1 receptor agonists and dual-incretin agents lead growth across diabetes and obesity. SGLT-2 inhibitors expand on cardiorenal and heart-failure evidence suited to UAE comorbidity patterns. Insulin remains a steady volume base with interest in newer analogues and connected devices. Continuous glucose monitoring and digital adherence tools are notably mature in UAE private endocrinology. Obesity pharmacotherapy is the fastest-emerging adjacent segment, propelled by both clinical demand and a private wellness market.',
    },
    {
      question: 'What local factors affect diabetes adoption and adherence in the UAE?',
      answer:
        'Ramadan fasting requires structured dose-adjustment counselling for insulin and some agents, and adherence follows cultural and lunar-calendar cycles. Emirate-level insurer policy determines coverage and prior authorization, and the obesity-versus-diabetes framing decides eligibility for incretin therapy under many plans. A large expatriate population adds continuity-of-care and language considerations, and wellness-driven self-pay demand can distort utilisation analytics. BioNixus recommends capturing these payer, cultural, and channel gates in qualitative work alongside prescribing surveys so forecasts reflect real reimbursable adherence rather than label assumptions.',
    },
    {
      question: 'How does BioNixus help diabetes and metabolic teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE diabetes and metabolic programmes: endocrinologist and primary-care adoption studies, insurer and payer coverage interviews across MOHAP, DHA, and DOH, GLP-1 supply-and-coverage tracking, obesity-channel and self-pay research, and KOL mapping across endocrinology and obesity care. We separate insured from self-pay and medical-tourism demand and align deliverables to launch, coverage-strategy, or indication-expansion milestones, connecting UAE findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include emirate and payer archetypes, coverage and switching maps, access-risk assessments, and committee-ready executive summaries. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
